Table 6. The MTHFR Glu429Ala polymorphism and overall survival in the validation cohort patients (stratified by treatment with 5-Fluorouracil).

	Treated with 5-FU			Not treated with 5-FU
	Validation cohort (n = 87)			Validation cohort (n = 141)
#Variable	HR (95% CI)	p-value	n	HR (95% CI)	p-value	n
MTHFR Glu429Ala		0.676			0.032
AC vs AA	1.34 (0.70–2.56)	0.382	41 vs 39	1.70 (1.10–2.63)	0.017	57 vs 71
CC vs AA	1.07 (0.35–3.29)	0.903	7 vs 39	0.82 (0.36–1.88)	0.637	13 vs 71
Age	1.02 (0.99–1.05)	0.189		1.06 (1.03–1.08)	<0.001
Stage		<0.001			<0.001
II vs I	0.54 (0.14–2.10)	0.372	26 vs 6	1.36 (0.73–2.54)	0.331	56 vs 36
III vs I	1.42 (0.42–4.78)	0.570	42 vs 6	3.61 (1.83–7.12)	<0.001	23 vs 36
IV vs I	6.32 (1.72–23.16)	0.005	13 vs 6	11.32 (5.52–23.20)	<0.001	26 vs 36
MSI-H vs MSI-L/MSS	0.34 (0.08–1.46)	0.146	8 vs 79	0.37 (0.15–0.94)	0.037	13 vs 128

5-FU: 5-fluorouracil, CI: confidence interval, HR: hazard ratio, n: number of patients, vs: versus.

#The referent categories are underlined. Please note that reflecting the small numbers of patients, the CIs for the effect estimate in stage IV patients are quite wide and should not be interpreted as an accurate estimation.